KELIX Bio

KELIX Bio is a biopharmaceutical company that specializes in the development and distribution of high-complexity generic medicines, targeting underserved populations in emerging markets, particularly in Egypt and North Africa. The company focuses on differentiated therapeutic areas, including oncology, and aims to enhance the availability and affordability of essential pharmaceuticals in these regions. By leveraging innovation and cost leadership, KELIX Bio seeks to address the challenges faced by healthcare systems in providing access to critical medications, ultimately improving health outcomes for patients in its markets.

Rajiv Nakani

Group Finance Director

5 past transactions

DiabTec

Acquisition in 2025
DiabTec is a unit of Julphar that manufactures recombinant human Insulin API services.

Pharmaceutical Institute

Acquisition in 2022
Pharmaceutical Institute is a prominent manufacturer and distributor of pharmaceutical products located in Ain El Aouda, Morocco. The company specializes in producing a wide range of medications that address various health issues, including fungal infections, inflammation, digestive disorders, urogenital conditions, central nervous system ailments, and antihistamines. In addition to its core manufacturing operations, Pharmaceutical Institute offers contract manufacturing services to various pharmaceutical brands worldwide. With a robust distribution network and established manufacturing capabilities, the company is poised to support efforts to enhance access to affordable, life-saving pharmaceutical products across Africa.

Chemi

Acquisition in 2021
Chemi is an Italian pharmaceutical company.

Celon Laboratories

Acquisition in 2020
Founded in 2001, Celon Laboratories is a Hyderabad-based pharmaceutical company specializing in the development, manufacturing, and marketing of niche therapy products. Its portfolio includes oncology and critical care products, available in various dosage forms, serving markets across Asia Pacific, Africa, Latin America, CIS countries, and Eastern Europe.

ADWIA Pharmaceuticals

Acquisition in 2020
ADWIA Pharmaceuticals is an Egyptian company that specializes in the development, manufacturing, and marketing of health products for both human and veterinary use. The company offers a range of generic drugs and focuses on animal health products tailored for various species in production markets. Additionally, ADWIA Pharmaceuticals is involved in the production formulation and delivery of human pharmaceutical and pesticide products, catering to a wide array of health needs across different sectors.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.